Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | BCL3 | P20749 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872804 | 0.96 | BCL3 (0.47) | MEN1KMT2ATDP1BCL3POLB | |
| SCHEMBL5872857 | 0.91 | BCL3 (0.48) | MEN1KMT2ATDP1BCL3POLB | |
| SCHEMBL6035427 | 0.90 | MEN1 (0.48) | MEN1KMT2ATDP1BCL3POLB | |
| SCHEMBL6035215 | 0.88 | MAP2K2 (0.56) | MEN1KMT2ATDP1BCL3POLB | |
| SCHEMBL7854395 | 0.83 | TSHR (0.46) | MEN1KMT2ATDP1BCL3POLB | |
| SCHEMBL6035719 | 0.83 | BCL3 (0.55) | MEN1KMT2ABCL3POLBALDH1A1 | |
| SCHEMBL6035287 | 0.82 | BCL3 (0.59) | KMT2ABCL3POLBLMNA | |
| SCHEMBL6036026 | 0.81 | MEN1 (0.48) | MEN1KMT2ATDP1MAP2K2MAP2K1 | |
| SCHEMBL5872928 | 0.81 | MEN1 (0.49) | MEN1KMT2ATDP1MAP2K2MAP2K1 | |
| SCHEMBL5873019 | 0.81 | MAPT (0.47) | MEN1KMT2ATDP1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | MEN1 2841/4885KMT2A 636/4885TDP1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.